KPTI

Karyopharm Therapeutics

Last Updated:

Q3 '20

Price

quotes and stock data delayed 15 minutes

Cash

$260M

Burn Rate (Qtr)

-$53.5M

Company Profile

Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is an oncology-focused pharmaceutical company dedicated to the discovery, development, and commercialization of novel first-in-class drugs directed against nuclear export and related targets for the treatment of cancer and other major diseases.

Drug Pipeline

Click on drug name or indication to see upcoming trial info, prior data, and more general information

Drug | Disease (links)

Stage (next event)

Catalyst Date

XPOVIO

Multiple myeloma (DLBCL if approved)

Approved (quarterly XPOVIO revenue)

5/8/2020 (estimated)

XPOVIO (Selinexor)

Multiple myeloma (Penta-Refractory) | STORM

Quarterly Sales (Approved)

February 05, 2021

Selinexor (Xpovio)

Diffuse Large B -Cell Lymphoma DLBCL | SADAL

Quarterly Sales

February 05, 2021 (Est)

Selinexor

Endometrial Cancer | SIENDO

Phase 2/3

TBD

Selinexor

Diffuse Large B- Cell Lymphoma (combination with rituximnab-gemcitabine-dex-platinum) | XPORT_DLBCL-030)

Phase 3

TBD

Selinexor

Multiple myeloma (Relapsed/Refractory) | BOSTON

PDUFA

March 19, 2021

Selinexor

Liposarcoma | SEAL

NDA submission

Q1 2021

Eltanexor

Myelodysplastic Syndrome (MDS)

Phase 2

TBD

Eltanexor

Colorectal Cancer (CRC) and Prostate Cancer (PrC)

Phase 1/2

TBD

Selinexor

Multiple myeloma (Relapsed/Refractory and Front line) | STOMP

Phase 1b/2

TBD

Selinexor, XPOVIO (Moderate or Severe COVID-19)

COVID-19 Therapy

Phase 2 (Data)

TBD

KPT-9274

Cancer

Phase 1

TBD

KPT-9274

Solid Tumors & Lymphoma

Phase 1

TBD

Selinexor

Diffuse Large B-cell Lymphoma (Combination with Chemo and non-chemo) | XPORT-DLBCL-025

Phase 1

TBD

Selinexor

CRC (combination with pembrolizumab) and NSCLC (combination with docetaxel) | XPORT-STP-027

Phase 1

TBD

Recent Posts

See what the community is saying - click to see full post

KPTI - Karyopharm Reports Positive Phase 3 SEAL Data in Oral Presentation at The Connective Tissue Oncology So

KPTI - Karyopharm Reports Third Quarter 2020 Financial Results and Highlights Recent Company Progress

KPTI - Karyopharm Announces Phase 3 SEAL Study Meets Primary Endpoint with Significant Increase in Progression

KPTI - Karyopharm to Report Third Quarter 2020 Financial Results on November 2, 2020

KPTI - Karyopharm Announces Selinexor Clinical Data to be Presented ISIRV-AVG Virtual Conference on Therapeuti

#KPTI - #PDUFA Date for #XPOVIO as a Treatment for Patients with Multiple Myeloma

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

  • Twitter Social Icon
  • LinkedIn Social Icon